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Feedback loopAccumulating evidence indicates that some miRNAs could form feedback loops with their targets to ﬁne-tune
tissue homeostasis, while disruption of these loops constitutes an essential step towards human tumorigenesis.
In this study, we report the identiﬁcation of a novel negative feedback loop formed betweenmiR-139 and its on-
cogenic target Jun. In this loop, miR-139 could inhibit Jun expression by targeting a conserved site on its 3′-UTR,
whereas Jun could induce miR-139 expression in a dose dependent manner through a distant upstream regula-
tory element. Interestingly, aberration in this loop was found in human gastric cancer, where miR-139 was
down-regulated and inversely correlated with Jun expression. Further functional analysis showed that restored
expression of miR-139 in gastric cancer cells signiﬁcantly induces apoptosis, and inhibits cell migration and
proliferation as well as tumour growth through targeting Jun. Thus, our data strongly suggests a role of aberrant
miR-139/Jun negative feedback loop in the development of human gastric cancer and miR-139 as a potential
therapeutic target for gastric cancer. Given that miR-139 and Jun are deregulated in many cancers, our ﬁndings
here might have broader implication in other types of human cancers.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
MicroRNAs (miRNAs) are a class of ~22 nucleotides that are single
strand non-coding RNAs that typically repress target genes at post-
transcriptional level. A large number of studies have implicatedmiRNAs
in almost all kinds of human cancers, and altered miRNA levels can
result in aberrant expression of gene products that may contribute to
cancer development [1–3].
Recent studies have found that miRNAs often form composite feed-
back or feedforward loops with their targets, which contributes to
robustness of biological processes [4], decreases noise in gene regulation
systems [5], andmight provide amechanismof high informationﬂow for
the coordinate and adaptable control of miRNA and transcription factor, 20 Dongdajie, Beijing 100071,
y, 20Dongdajie, Beijing 100071,
nology, 20 Dongdajie, Fengtai
).
), yangx@bmi.ac.cn (X. Yang),
theﬁrst three authors should betarget regulons [6]. These feedback loops might function in normal
development as well as in inﬂammatory response and cancer [7–13].
In this study, we analysed the functional enrichment of miR-139
putative targets, suggesting that miR-139 might play important roles in
cancer-related functions and Jun might play central roles in miR-139-
mediated functions, and then showed that miR-139, down-regulated in
human gastric cancer, might play tumour suppressive roles through reg-
ulating the expression of Jun, an important component of the activator
protein-1 (AP-1) transcription factor. Conversely, we also observed that
Jun could induce miR-139 expression, probably through a distant
upstream regulatory region. Hence, we provide the ﬁrst evidence that
Jun is regulated by miR-139 and the Jun/miR-139 feedback loop might
be involved in human gastric cancer.
2. Materials and methods
2.1. Plasmids
AP1-luc luciferase reporter construct was made by inserting AP1 re-
sponsive element fused to aminimal TA promoter into multiple cloning
sites in pGL3-basic reporter construct (Promega,Madison, USA). For the
expression of miR-139, genomic fragment of humanmiR-139 precursor
was ampliﬁed by PCR and subcloned into pIRES2-EGFP (Clontech).
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described between the Bgl II and Mlu I sites [3]. Overlapping PCR was
performed to mutate the miR-139 target site in the Smad4 3′-UTR,
using two additional primers, and the products were subcloned into
pGL3-CM.
R (WT)-luc was constructed by cloning the distal region upstreamof
miR-139 into pGL3-promoter reporter construct, and R(ΔJunBS)-luc
was obtained by mutating Jun binding site through overlapping PCR.2.2. Cell culture and transfection
AGS (gastric carcinoma, ATCCCRL-1739), SGC-7901 (gastric carcino-
ma) and SNU-16 (gastric carcinoma, ATCC CRL-5974) were cultured in
Roswell Park Memorial Institute formulation 1640 (RPMI-1640) sup-
plemented with 10% fetal bovine serum. For transient transfections,
the cells were transfected with the aforementioned constructs in 6-cm
ﬂasks, protein lysates and total RNAs were collected at the indicated
time points. For stable transfection, SGC-7901 cells were transfected
with the miRNA expression construct or corresponding control con-
struct in 6-well plates and selected using G418.2.3. Proliferation assay
SGC-7901, AGS and SNU-16 cells transfected as indicated were
subject to MTT assay (Life technology) according to the manufacturer's
recommendations. Experiments were repeated three times, and data
represented as the mean of quadruplicate wells ± SEM.2.4. Migration and invasion assays
Cells cotransfected with miR-139 and miR-139 inhibitors or corre-
sponding controls were cultured to conﬂuence and then wounded
using a white pipette tip. Three wounds were made for each sample,
and migration distance was photographed and measured at zero time,
after 48 h and 60 h.
For cell invasion assay, cells were seeded on matrigel-coated poly-
carbonate membrane insert in a transwell apparatus and maintained
in RPMI-1640. RPMI-1640 containing 10% FBS was added to the lower
chamber. After incubation for 12 h at 37 °C, cells on the top surface of
the insert were removed and cells that migrated to the bottom surface
of the insert were ﬁxed and stained by crystal violet and then subjected
to microscopic inspection.2.5. Flow cytometry
For the quantiﬁcation of apoptosis, the cells were washed in
cold PBS, incubated with Annexin V-PE and 7-Amino-Actinomycin D
(7-AAD) (Southern Biotech, Birmingham, AL, USA) for 15 min in the
dark and analysed within 1 h. Flow cytometry was performed using a
Fluorescence-Activated Cell Sorting (FACS) Calibur Flow Cytometer
with CellQuest 3.0 software (BD Biosciences, San Jose, CA, USA) or
winMDI software (V2.9; Purdue University, West Lafayette, USA). For
the measurement of cell cycle, 2–3 × 106 cells were ﬁxed in 70% cold
ethanol, treated with RNase A and stained with propidium iodide
(Sigma). All analyses were performed in triplicate, and 20,000 gated
events/samples were counted.Fig. 1. MiR-139 directly inhibits Jun expression. A, cross predicted miR-139 targets were sub
Cytoscape. B, bars show betweenness centrality of the top 10 targets. C, bars show relative m
constructs or inhibitors as indicated;western blots show that Jun protein levelswere inhibited b
were visualized in UCSC browser. Ago CLIPed putativemiR-139 binding site wasmarked red. Bo
Watson–Crick pairing. Unpaired region inmutated constructs were shown in grey and underlin
inhibitors, pGL3-basic as negative reporter control. F, overexpression ofmiR-139 reduced the luc
vector control (pGL3-CM), whereas this regulation was abolished when the miR-139 target-bi2.6. Soft agar assays
Transfected cells were plated in 0.25% agar on top of 0.5% agar, both
containing 10% FBS in RPMI-1640. After two weeks, colonies with 50
cells or more were counted.
2.7. Local tumour growth
Tumour cell suspensions (107 cells/100 μl PBS) of either overexpres-
sion or mock cell lines were inoculated into the thigh of female nude
mice. 40 days after implantation, mice were killed and tumours were
weighted and photographed.
2.8. Luciferase reporter assay
Luciferase reporter assays were performed as described [3]. Brieﬂy,
the reporter plasmids were co-transfected using lipofectamine 2000
reagent (Life technology) with the miR-139 expression plasmid or
miR-139 antisense oligos and the vector phRG-TK (Promega), which ex-
presses synthetic Renilla luciferase to normalize the transfection efﬁ-
ciency. Luciferase activities were measured using the Dual-Luciferase
Reporter Assay reagent (Promega) on a LB 960 Centro XS3 luminometer
(Berthold Technologies, GmbH & Co. KG, Bad Wildbad, Germany). Each
experiment was performed in triplicate, and the data represent the
mean ± SD of three independent experiments.
2.9. Real-time RT-PCR for miRNA and mRNA analysis
Total RNA was isolated with Trizol reagent (Life technology), and
Reverse transcription was performed using with oligo dT primers and
random N6 primers for mRNA and stem-loop RT primer for miRNA
with Superior III RT supermix (Innogene biotech, Beijing, China). The
real-time PCR primers used are available on request. Real-time PCR
was performed using the IQ5 system (BioRad) with UltraSYBR Mixture
(Innogene), and expression was quantiﬁed relative to a housekeeping
geneGAPDH formRNAandU6 formiRNA. All experimentswere repeated
at least three times.
2.10. Western blot
Western blots were carried out using antibodies against Jun (#9165,
Cell Signalling Technology, Danvers, MA, USA), p21 (#2946, Cell Signal-
ling Technology, Danvers, MA, USA), c-Myc (#9402, Cell Signalling
Technology, Danvers, MA, USA), Cyclin D1 (#2978, Cell Signalling
Technology, Danvers, MA, USA) β-Actin (A5316, Sigma) and GAPDH
(CW0101, Cowin Biotech, Beijing, China).
2.11. ChIP-qPCR
ChIP was performed using EZ-Magna ChIP™ G-Chromatin immuno-
precipitation Kit (Millipore, 17-409, Darmstadt, Germany) following
manufacturer's guide with Jun antibody (Cell Signalling Technology,
#9165) or IgG control (#2729, Cell Signalling Technology). ChIPed
DNA was subjected to qPCR analyses using regulatory region primers
(F: TCGGTGTCAGCATCACACAA; R: GGAGTGTGGGTGAGTCACTG) and
miR-139 locus primers (F: CAGACTCCGGCTTCAGTTGT; R: AGGAGGCA
GGAGCTGGAATA).jected for KEGG pathways analysis, and the target-pathway network was visualized in
iR-139 expression as assessed by RT-qPCR in SGC-7901 cells transfected with miR-139
ymiR-139 and reversed bymiR-139 inhibitors. D, top: PAR-CLIP data compiled by Starbase
ttom: sequence alignment of putativemiR-139-binding site in the Jun-3′-UTR. Lines show
ed. E, AP-1 responsive reporter activity was inhibited bymiR-139 and reversed bymiR-139
iferase activity of thewild-type Jun-3′-UTR reporter (Luc-Jun (WT)), compared to negative
nding site in Jun-3′-UTR was mutated (Luc-Jun (Δ)) as indicated.
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To determine chromatin interaction frequency betweenmiR-139 up-
stream regulatory element and miR-139 locus, 3C assay was preformed
largely as described [14]. Brieﬂy, SGC-7901 cells were cross-linked by
1% formaldehyde. After cross-linking, nuclei were isolated and digested
with Pst I restriction enzyme (NEB). The digested nuclei were diluted
and intra-complex ligated with T4 DNA ligase (NEB), after reverse
cross-linking by proteinase K (Thermo Scientiﬁc), ligation frequencies
of restriction fragments are analysed by PCR, using primers speciﬁc
for the restriction fragments of interest (available upon request), all
3C-PCR products were validated by sanger sequencing.A
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dependently.2.13. Bioinformatic analysis
MiR-139 expression proﬁling data in gastric cancer were downloaded
fromNCBI GEO database, comparison between gastric cancer and normal
tissues were done byWilcoxon test, and data were plotted with beanplot
R package.
TargetScan6.2 (http://www.targetscan.org), PicTar(http://pictar.
mdc-berlin.de), PITA (genie.weizmann.ac.il/pubs/mir07/mir07_
prediction.html) and Starbase (http://starbase.sysu.edu.cn) were
used to predict miR-139 targets. MiR-139 targets were predicted and
downloaded from the respective databases with default or stringent
settings and then compared and combined with these databases. Only0
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485Y. Zhang et al. / Biochimica et Biophysica Acta 1853 (2015) 481–488targets that cross proved by at least 2methodswere selected for further
analyses. Gene ontology analysis and pathway enrichment analysis
were done in DAVID website (http://david.abcc.ncifcrf.gov). The
target-pathway network was analysed and visualized in cytoscape
software.
2.14. Statistical analysis
Student t tests were performed to assess the signiﬁcance of treat-
ments vs. controls. Signiﬁcance of differences in miR-139 levels
between normal and gastric cancer tissues was tested by Wilcoxon
rank sum test. The relationship between the expression of miR-139
and Jun in gastric cells and tissues was determined using the Spearman
rank correlation. P b 0.05 was considered statistically signiﬁcant.
3. Result
3.1. MiR-139 negatively regulates Jun expression
Down-regulation of miR-139 has been reported in several kinds of
human cancers [15,16], and therefore a tumour suppressive role was
proposed formiR-139, however, its exact role and the underlyingmech-
anisms remain elusive. Computational predictions, based on Starbase
data from PAR-CLIP experiments [17] combined with pre-compiled
miRNA target databases identiﬁed an array of genes as putative targets
of miR-139. Pathway analysis on these candidate targets indicated
cancer-related pathways as top pathways that miR-139 might regulate
(Supplementary Fig. S1A), and gene ontology analysis indicated thatA
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Fig. 3. Inverse correlation betweenmiR-139 and Jun in gastric cancer tissues. A,miR-139 and Jun
expression was down-regulated in gastric cancer tissues and inversely correlates with Jun. Cor
tative results of expression proﬁling ofmiR-139 (bars, as assessed byRT-qPCR) and Jun (Wester
T refers to tumour tissue. C, bean plots depicting the distribution ofmiR-139 levels in normal an
with cisplatin/ﬂuorouracil or not. P value indicates signiﬁcance returned by Wilcoxon rank summiR-139 targets might play important roles in transcription regulation,
cell proliferation andmigration (Supplementary Fig. S1B). Interestingly,
one of the candidate target Jun, a member of activator protein 1 (AP-1)
family, was found to be in the centre of target-pathway (Figs. 1A and1B)
and target-function networks (Supplementary Fig. S2). Importantly, all
of the methods we used predicted Jun as a miR-139 putative target.
We therefore examined whether miR-139 could repress Jun expres-
sion. Indeed, protein levels of Jun were reduced upon miR-139 overex-
pression in SGC-7901, AGS and SNU-16 cells, which could be readily
reversed by miR-139 inhibitors (Fig. 1C and Supplementary Figs. S5A
and S5B). Inhibition of miR-139 induced c-Jun and its target c-Myc
expression (Supplementary Figs. S5C and S5D). Meanwhile, miR-139
inhibited Jun-mediated AP-1 activity, as assessed by AP-1 responsive
reporter assay (Fig. 1E). We were also able to observe that expression
of Jun canonical targets c-Myc, Baculoviral IAP Repeat-Containing 5
(BIRC5, Survivin) and Cyclin D1, were signiﬁcantly down-regulated
upon miR-139 overexpression, which could be rescued by Jun restora-
tion (Supplementary Fig. S5E–S5G). Furthermore, computational
analysis revealed that Jun 3′-UTR harbours one putative binding site
for miR-139 which is conserved across various species, and this target
site was also identiﬁed in a high throughput Ago PAR-CLIP study [18]
(Fig. 1D). To conﬁrm the potential interaction experimentally, a reporter
construct was made by sub-cloning human Jun 3′-UTR downstream of
the ﬁreﬂy luciferase coding sequence, and cotransfected into SGC-7901
cells with miR-139-expressing construct and/or miR-139 inhibitors.
Overexpression of miR-139 decreased luciferase activity as compared
to negative controls, while miR-139 inhibitors increased luciferase activ-
ity and reversed miR-139-mediated repression; furthermore, mutationN P T
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miR-139 inhibitors on luciferase activity (Fig. 1F). These ﬁndings sug-
gested that miR-139 could regulate Jun expression through a conserved
binding site on its 3′-UTR.
3.2. Jun positively regulates miR-139 transcription
In an attempt to explore the mechanisms underlining miR-139's
regulation, we explored data from ENCyclopedia Of DNA Elements
(ENCODE) project and found a putative regulatory element character-
ized by H3K4Me1 and H3K27Ac peaks located approximately 10 kb
upstream of miR-139 locus, which harboured an AP-1 motif and also
captured by Jun ChIP-seq inferred from ENCODE data (Fig. 2A). Jun
was conﬁrmed to bind to the potential regulatory element by using
ChIP-qPCR assay in both SGC-7901 and SNU-16 cells, strikingly Jun
can also bind to miR-139 locus, around which there is no AP-1 motif
(Fig. 2B and Supplementary Fig. S3A). Public Chromatin Interaction
Analysis by Paired-End Tag Sequencing (ChIA-PET) data indicated that
this regulatory element loops tomiR-139 locus. To conﬁrm this physical
chromatin interaction in gastric cancer cells, we preformed chromo-
somal conformation capture (3C) assay in SGC-7901 cells. Data shown
in Fig. 2A suggests high frequency of cross-link between these two
fragments, providing structure basis for Jun binding to miR-139 locus.
Further, to validate the enhancer activity of this element, we subcloned
it into pGL3 reporter construct, then co-transfected with Jun overex-
pression plasmid and/or treated with Phorbol-12-myristate-13-acetate
(PMA), which induces both Jun level and activity. Reporter assay
indicated that the regulatory element (R) conferred approximately 5NC 139
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Fig. 4. Involvement ofmiR-139/Jun feedback loop in gastric cancer cells. A, stable overexpressio
Jun, as assessed by FCM analysis of Annexin V-positive cells. B, growth curve as assayed by MT
which was reversed by miR-139 inhibitors and Jun restoration. C, Jun restoration reversed miR
200 μm.times luciferase activity compared to pGL3 negative control, and Jun
could dramatically increase activity of this element, whereas when the
Jun binding site was deleted (R(ΔJunBS)), the activity as well as Jun
responsiveness to PMA was largely impaired (Fig. 2C). Consistently,
the gradually increasing Jun expression by ectopic transfection
increased miR-139 expression in a dose dependent manner in two
tested gastric cancer cells (Fig. 2D and Supplementary Fig. S3B). These
data indicate that Jun could induce miR-139, probably through
upstream regulatory element, which in turn targets Jun for inhibition,
thus forming a negative feedback loop.
3.3. Aberrant miR-139/Jun feedback loop in human gastric cancer
To establish a clinical implication for themiR-139/Jun feedback loop,
we checked the expression of miR-139 and Jun in a set of pair-matched
gastric cancer samples; as a result, Junwas up-regulated in 16 of 19 can-
cerous specimens examined. Importantly, increased Jun expressionwas
signiﬁcantly correlated with decreased miR-139 (Figs. 3A and 3B)
(Spearman's Ρ=−0.753, P=3.05×10−4), suggesting an involvement
of miR-139/Jun feedback loop in human gastric cancer. Downregulation
of miR-139 in gastric cancer tissue was also supported by previous mi-
croarray datasets and reports [19] (Fig. 3C). We also determined levels
of miR-139 and Jun in gastric cancer cell line SGC-7901, AGS and SNU-
16, and again found an inverse correlation between expressions of
these two genes (Supplementary Fig. S4).
To explore the roles of miR-139/Jun feedback loop in human gastric
cancer cells, we carried out experiments in SGC-7901, AGS and SNU-16
cells. We observed that while apoptosis was signiﬁcantly higher139i 139+Jun
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n ofmiR-139 induced apoptosis, whichwas reversed bymiR-139 inhibitors and rescued by
T assay indicated miR-139 overexpression confers inhibited cell growth in SGC-7901 cells,
-139 inhibition on cell invasion, as assessed by matrigel-coated transwell assay. Scale bar:
487Y. Zhang et al. / Biochimica et Biophysica Acta 1853 (2015) 481–488(Fig. 4A, Supplementary Fig. S6), cell proliferation, migration and
invasion ability were signiﬁcantly impaired in miR-139 restored cells
(Figs. 4B, 4C and Supplementary Fig. S7), which could be reversed by
miR-139 inhibitors, supporting a tumour suppressive role of miR-139
in gastric cancer. Importantly, miR-139 likely executes these functions
largely by targeting Jun oncogene, as restored Jun expression abolished
both the tumour suppressive effects and molecular changes caused by
miR-139 overexpression (Fig. 4, Supplementary Fig. S5E–5G and
Fig. S6). Next, soft agar assay was performed to test role of miR-139 in
colony formation. Overexpression of miR-139 could reduce anchorage
independent cell growth, while restoration of Jun could rescue this ef-
fect (Fig. 5A). The tumour suppressive role of miR-139 was conﬁrmed
in xenograft tumour model, where overexpression of miR-139 resulted
in signiﬁcant smaller tumour growth (Figs. 5B and 5C), which is coinci-
dent with increased levels of p21 (WAF/CIP1) and decreased levels of
Jun and c-Myc (Fig. 5D). Interestingly, the expression changes of miR-
139 and Jun in xenograft tumour model are not as dramatic as in cell
line, we reasoned that cells with high level of miR-139 and hence low
level of Junwould lose competitive advantage in heterogeneous tumour
mixture during the process of tumorigenesis, which is consistent with
the fact that miR-139 was frequently reduced, and thus Jun expression
increased, in clinical gastric cancer samples.
4. Discussion
MiR-139 is consistently reported to be downregulated in several
kinds of tumours, and involved in invasion and metastasis of colorectal
cancer and hepatocellular carcinomaby targeting Rho-Kinase 2 [16] and
the type I IGF-IR [20] respectively. Here, we preformed functional
enrichment analysis on putative miR-139 targets and suggested
that miR-139 most likely plays roles in cancer related functions,
and oncogenic Jun might play central roles in these complicated
miR-139-function networks. Experimental data conﬁrmed that5
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Fig. 5.MiR-139 inhibits tumorigenesis in vitro and in vivo. A, Cells transfected as indicatedwere
and number were reduced by miR-139 overexpression, whereas Jun rescued miR-139 effects o
mice with control cells (Vec) and cells over-expressingmiR-139 (139). Total tumour volume di
icant, as checked byWilcoxon rank sum test. C, Overexpression ofmiR-139was conﬁrmed in xe
tumours.miR-139 inhibits Jun expression and affects gastric cancer via targeting
Jun. So it's proposed here that miR-139 exerts tumour suppressive
roles by coordinately targeting an array of related oncogenes includ-
ing Jun.
Previous studies have established that Jun plays essential roles in cell
growth, survival, migration and invasion, exerting oncogenic roles in
various cancers [21–24]. Activity of Jun is also critical for the initiation
and progression of gastric cancer [25,26]. Chemical compounds and bi-
ological factors, such as Helicobacter pylori [27,28], often act in gastric
cancer through regulating Jun, while its regulation by miRNAs in this
disease has not been reported yet. Here we showed that miR-139, a
miRNA down-regulated in human gastric cancer, could target Jun for
expression inhibition, providing a novel level of regulation for Jun in
gastric cancer.
Interestingly, we found that Jun could also induce miR-139 expres-
sion, probably through an upstream distant regulatory element, which
co-localize spatially to miR-139 locus, in a dose dependent manner in
gastric cancer cells. Thus, all these data are consistent with the notion
that Jun forms a self-limiting feedback loop with miR-139, in which
Jun induces miR-139 expression through a distal upstream regulatory
element,whilemiR-139 represses Jun expression to ensure tight control
of its oncogenic activity. This unilateral feedback loop is supposed to
contribute to homeostasis between oncogenic Jun and tumour suppres-
sivemiR-139. Interestingly, despite the high level of Jun in gastric cancer
cells, miR-139 stays in low expression level, given that miR-139 is often
epigenetic or post-transcriptional inactivated [15,29], we speculate that
negative regulatory mechanisms other than Jun induction may domi-
nate the regulation of miR-139 in gastric cancer, which makes the can-
cer cells insensitive to the lost-controlled Jun expression. In addition to
gastric cancer, deregulation of miR-139 and/or Jun was also reported in
several kinds of human cancer besides gastric cancer [16,30–32], we
therefore could expect a more general role of aberrant miR-139/Jun
feedback loop in human tumorigenesis.Vec 139 Vec 139
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grown in soft agar. Representative imageswere shown. Scale bar: 100 μm. Both colony size
n colony growth. B, Xenograft tumours in nude mice over 4 weeks following injection of
fference between the Vec and 139 injected after 4 weeks of growth was statistically signif-
nograft tumours. D,miR-139 inhibited Jun, c-Myc and induced p21 expression in xenograft
488 Y. Zhang et al. / Biochimica et Biophysica Acta 1853 (2015) 481–488In summary, our study expanded insights into the roles and regula-
tion of miR-139 in gastric cancer, provided the ﬁrst evidence for direct
Jun-miRNA feedback loop in human cancers, which might contribute
to our understanding of the complicated mechanisms underlying
gastric cancer, and may enhance the development of new therapeutic
regimens in treating this disease.
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